Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laetitia Collet

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Acta Crystallographica. Section D, Structural Biology|February 9, 2021
Glycoside hydrolase family 5: structural snapshots highlighting the involvement of two conserved residues in catalysisLaetitia Collet, Corinne Vander Wauven, Yamina Oudjama, et al.
Acta Crystallographica. Section D, Structural Biology|March 2, 2022
Highlighting the factors governing transglycosylation in the GH5_5 endo-1,4-β-glucanase RBcel1Laetitia Collet, Corinne Vander Wauven, Yamina Oudjama, et al.
Acta Crystallographica. Section D, Structural Biology|May 8, 2026
Definition of the catalytic cleft and product profile of a GH5_5 cellulase from Thermoascus aurantiacusLaetitia Collet, Agathe Denys, Yamina Oudjama, et al.
The Oncologist|July 21, 2021
Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer CenterNathalie Olympios, Laetitia Collet, Marianne Paesmans, et al.
Cancers|February 15, 2022
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast CancersLaetitia Collet, Julien Péron, Frédérique Penault-Llorca, et al.
Frontiers in Oncology|March 28, 2024
BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesLaetitia Collet, Brunhilde Hanvic, Margherita Turinetto, et al.
Cancers|June 2, 2021
Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective CohortLaetitia Collet, Lidia Delrieu, Amine Bouhamama, et al.
Acta Crystallographica. Section D, Structural Biology|June 18, 2019
Crystal structure determination of Pseudomonas stutzeri A1501 endoglucanase Cel5A: the search for a molecular basis for glycosynthesis in GH5_5 enzymesRaphaël Dutoit, Maud Delsaute, Laetitia Collet, et al.
Journal of Clinical Medicine|February 11, 2023
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and ChallengesXiaoxiao Wang, Laetitia Collet, Mattia Rediti, et al.
BMC Cancer|July 14, 2023
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective studyAgathe Vienne, Laetitia Collet, Thomas Chevalier, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Acta Crystallographica. Section D, Structural Biology|February 9, 2021
Glycoside hydrolase family 5: structural snapshots highlighting the involvement of two conserved residues in catalysisLaetitia Collet, Corinne Vander Wauven, Yamina Oudjama, et al.
Acta Crystallographica. Section D, Structural Biology|March 2, 2022
Highlighting the factors governing transglycosylation in the GH5_5 endo-1,4-β-glucanase RBcel1Laetitia Collet, Corinne Vander Wauven, Yamina Oudjama, et al.
Acta Crystallographica. Section D, Structural Biology|May 8, 2026
Definition of the catalytic cleft and product profile of a GH5_5 cellulase from Thermoascus aurantiacusLaetitia Collet, Agathe Denys, Yamina Oudjama, et al.
The Oncologist|July 21, 2021
Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer CenterNathalie Olympios, Laetitia Collet, Marianne Paesmans, et al.
Cancers|February 15, 2022
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast CancersLaetitia Collet, Julien Péron, Frédérique Penault-Llorca, et al.
Frontiers in Oncology|March 28, 2024
BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesLaetitia Collet, Brunhilde Hanvic, Margherita Turinetto, et al.
Cancers|June 2, 2021
Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective CohortLaetitia Collet, Lidia Delrieu, Amine Bouhamama, et al.
Acta Crystallographica. Section D, Structural Biology|June 18, 2019
Crystal structure determination of Pseudomonas stutzeri A1501 endoglucanase Cel5A: the search for a molecular basis for glycosynthesis in GH5_5 enzymesRaphaël Dutoit, Maud Delsaute, Laetitia Collet, et al.
Journal of Clinical Medicine|February 11, 2023
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and ChallengesXiaoxiao Wang, Laetitia Collet, Mattia Rediti, et al.
BMC Cancer|July 14, 2023
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective studyAgathe Vienne, Laetitia Collet, Thomas Chevalier, et al.
Pageof 2